In vitro: The combined use of glycolysis inhibitor WP1122 and HDAC inhibitors (such as sodium butyrate and sodium valproate) demonstrated significant synergistic anti-cancer effects, inhibiting the proliferation of GBM cells and inducing apoptosis.In vivo: In mouse models, the combination therapy significantly inhibited tumor growth, improved the survival rate of the mice, and no obvious toxicity was observed (70). The gene discussed is HDAC9; the disease is neoplasm.